Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A
- PMID: 1369413
- DOI: 10.1007/BF00376102
Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A
Abstract
A 300-fold adriamycin resistant variant (DLKP-A) of the human lung squamous cell carcinoma line DLKP was established by stepwise selection in increasing concentrations of adriamycin. Different levels of cross-resistance were observed towards VP-16, VM-26, colchicine, vincristine and, somewhat unexpectedly, cis-platin. Resistance was stable for at least 3 months in culture in the absence of drug. P-glycoprotein overexpression was detected by immunofluorescence and Western Blotting, and a direct causal role for P-glycoprotein overexpression in the resistant phenotype was established by transfection with an mdr1 specific antisense oligonucleotide. A modified cryopreservation procedure was necessary for the resistant variant line. The resistant population displays clonal heterogeneity with respect to resistance level. A higher frequency of double minute chromosomes was observed in DLKP-A when compared with the parental cell line.
Similar articles
-
Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs.Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230. Int J Cancer. 2004. PMID: 15239124
-
Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.Cancer Res. 1991 Oct 1;51(19):5275-83. Cancer Res. 1991. PMID: 1717144
-
Multiple drug resistance in the human ovarian carcinoma cell line OAW42-A.Eur J Cancer. 1993;29A(8):1078-81. doi: 10.1016/s0959-8049(05)80291-6. Eur J Cancer. 1993. PMID: 8100138
-
Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.Cancer Res. 1990 Sep 1;50(17):5392-8. Cancer Res. 1990. PMID: 1974823
-
Molecular biology of drug resistance.Breast Cancer Res Treat. 1987;9(1):5-16. doi: 10.1007/BF01806689. Breast Cancer Res Treat. 1987. PMID: 3297213 Review. No abstract available.
Cited by
-
Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.Int J Mol Sci. 2020 Oct 15;21(20):7613. doi: 10.3390/ijms21207613. Int J Mol Sci. 2020. PMID: 33076245 Free PMC article.
-
Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.Cytotechnology. 1993;12(1-3):265-88. doi: 10.1007/BF00744668. Cytotechnology. 1993. PMID: 7765329 Review.
-
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.Invest New Drugs. 2010 Aug;28(4):433-44. doi: 10.1007/s10637-009-9266-0. Epub 2009 Jun 5. Invest New Drugs. 2010. PMID: 19499189
-
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.Cancer Chemother Pharmacol. 2013 May;71(5):1357-68. doi: 10.1007/s00280-013-2136-7. Epub 2013 Apr 16. Cancer Chemother Pharmacol. 2013. PMID: 23589314 Free PMC article.
-
Modulation of P-gp expression by lapatinib.Invest New Drugs. 2011 Dec;29(6):1284-93. doi: 10.1007/s10637-010-9482-7. Epub 2010 Jul 6. Invest New Drugs. 2011. PMID: 20607587
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials